Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL2221135 | 1.00 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL28138343 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL28914 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL21057 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL149462 | 0.93 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Water SCHEMBL3908933 | 0.91 | USP2 (0.59) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Ammonia Solution, Strong SCHEMBL2719059 | 0.91 | USP2 (0.59) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Phosphoric Acid SCHEMBL1696409 | 0.86 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Propylamine SCHEMBL13737874 | 0.84 | USP2 (0.52) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Galactose SCHEMBL5699454 | 0.81 | USP2 (0.49) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022461-A1 | SULPHATED SUGARS TO INCREASE ACTIVITY OF SULPHATASES EN LYSOSOMAL STORAGE DISORDERS | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE (AU) | 2010-03-04 | — | — | WO | claimed |
| US-20100009007-A1 | Non-covalent modification of microparticles and process of preparing same | BAXTER INTERNATIONAL INC. (US) | 2010-01-14 | — | — | US | claimed |
| WO-2010006194-A2 | NON-COVALENT MODIFICATION OF MICROPARTICLES AND PROCESS OF PREPARING SAME | BAXTER INTERNATIONAL INC. (US) | 2010-01-14 | — | — | WO | claimed |
| WO-2023198917-A1 | HYDROGELS FOR SOFT TISSUE FILLING | Teoxane SA (CH) | 2023-10-19 | — | — | WO | disclosed |
| EP-2986140-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATMENT OF PETS | Nusirt Sciences, Inc. (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2968206-A1 | TREATMENT OF PETS WITH SIRTUIN ACTIVATORS | Nusirt Sciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014149434-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATMENT OF PETS | NUSIRT SCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149280-A1 | TREATMENT OF PETS WITH SIRTUIN ACTIVATORS | NUSIRT SCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20100009007-A1 | Non-covalent modification of microparticles and process of preparing same | BAXTER INTERNATIONAL INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2010006194-A2 | NON-COVALENT MODIFICATION OF MICROPARTICLES AND PROCESS OF PREPARING SAME | BAXTER INTERNATIONAL INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-1723252-A4 | TEMPORAL OR SPATIAL CHARACTERIZATION OF BIOSYNTHETIC EVENTS IN LIVING ORGANISMS BY ISOTOPIC FINGERPRINTING UNDER CONDITIONS OF IMPOSED ISOTOPIC GRADIENTS | UNIV CALIFORNIA (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20070219161-A1 | Preparation Process Of Oligoglycosaminoglycan, And Reducing End Glucuronic Acid Type Oligochondroitin Sulfate And Pharmaceutical Composition Comprising The Same | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1740620-A1 | PREPARATION PROCESS OF OLIGOGLYCOSAMINOGLYCAN, AND REDUCING END GLUCURONIC ACID TYPE OLIGOCHONDROITIN SULFATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-1723252-A1 | TEMPORAL OR SPATIAL CHARACTERIZATION OF BIOSYNTHETIC EVENTS IN LIVING ORGANISMS BY ISOTOPIC FINGERPRINTING UNDER CONDITIONS OF IMPOSED ISOTOPIC GRADIENTS | Regents of the University of California (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1603578-A2 | CYSTITIS TREATMENT WITH HIGH DOSE CHONDROITIN SULFATE | Stellar International Inc. (CA) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005092931-A1 | PREPARATION PROCESS OF OLIGOGLYCOSAMINOGLYCAN, AND REDUCING END GLUCURONIC ACID TYPE OLIGOCHONDROITIN SULFATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005087943-A1 | TEMPORAL OR SPATIAL CHARACTERIZATION OF BIOSYNTHETIC EVENTS IN LIVING ORGANISMS BY ISOTOPIC FINGERPRINTING UNDER CONDITIONS OF IMPOSED ISOTOPIC GRADIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2004073584-A2 | CYSTITIS TREATMENT WITH HIGH DOSE CHONDROITIN SULFATE | STELLAR INTERNATIONAL INC. (CA) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219161-A1 | Preparation Process Of Oligoglycosaminoglycan, And Reducing End Glucuronic Acid Type Oligochondroitin Sulfate And Pharmaceutical Composition Comprising The Same | OSTC, B3GAT3, CSGALNACT1 | USP2 1408/4885SLCO1B1 1156/4885LMNA 2246/4885 |
| US-20100009007-A1 | Non-covalent modification of microparticles and process of preparing same | CHMP4B, PHOSPHO1, PLTP | USP2 1003/4885SLCO1B1 3024/4885LMNA 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.